Status:
COMPLETED
Relative Bioavailability of Phase II and Phase III Formulations of AZD0530
Lead Sponsor:
AstraZeneca
Conditions:
Healthy
Eligibility:
All Genders
18-45 years
Phase:
PHASE1
Brief Summary
The aim of the study is to compare how different formulations of AZD0530 are absorbed by the body. As for all clinical trials, safety and tolerability of the drug will be evaluated.
Eligibility Criteria
Inclusion
- Female subjects must be of Non- child-bearing potential
- Body mass index between 19 and 30 kg/m2 and weigh between 50-100 kg
Exclusion
- Presence of any clinically significant illness
- Abnormal vital signs
- History of any conditions that may put the subject at risk by participating in the study
- Participation in another clinical study.
Key Trial Info
Start Date :
November 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2009
Estimated Enrollment :
18 Patients enrolled
Trial Details
Trial ID
NCT00771979
Start Date
November 1 2008
End Date
March 1 2009
Last Update
June 18 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Alderley Park, United Kingdom